The distribution and gender difference of CYP3A activity in Chinese subjects

British Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2003, Pages 264-269

  Zhu, Bing ^a   Liu, Zhao Qian ^a   Chen, Guo Lin ^a   Chen, Xiao Ping ^a   Ou Yang, Dong Sheng ^a   Wang, Lian Sheng ^a   Huang, Song Lin ^a   Tan, Zhi Rong ^a   Zhou, Hong Hao ^a  

^a Central South University   (China)

Author keywords

CYP3A; Gender; Menstrual cycle; Midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A; MIDAZOLAM; MIDAZOLAM MALEATE; NIFEDIPINE; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MENSTRUAL CYCLE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; MENSTRUAL CYCLE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; SEX CHARACTERISTICS;

EID: 0037349259     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01728.x     Document Type: Article

References (27)

1. Wilkinson GK. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity, in humans. J Pharmacokin Biopharm 1996; 24: 475-490.
2. Paulussen A, Lavrijsen K, Bohets H, et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000; 10: 415-424.
3. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38: 389-430.
4. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P4503A activity in humans. Mol Pharmacol 1996; 50: 52-59.
5. Kleinbloesem CH, Brummelen PV, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984; 33: 3721-3724.
6. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a larger population of healthy subjects. Biochem Pharmacol 1988; 37: 2507-2510.
7. Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH. Single plasma sampling to predict oral clearance of the CYP3A probe midazolam. Acta Phamacol Sin 2001; 22: 634-638.
8. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222-239.
9. Labbé L, Sirois C, Pilote S, et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000; 10: 425-438.
10. Carrillo JA, Kamos SI, Agundez JAG, Martinez C, Benitez J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit 1998; 20: 319-324.
11. Kassai A, Toth G, Eichelbaum M, Klotz U. No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokin 1988; 15: 319-325.
12. Wandel C, Bocker RH, Bohrer H, et al. Relationship between hepatic cytochrome P4503A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 1998; 26: 110-114.
13. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.
14. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275-283.
15. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68: 130-142.
16. Lobo J, Kack DB, Kendall MJ. The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers. Eur J Clin Pharmacol 1986; 30: 57-60.
17. Lemmens HJM, Burm AGL, Hennis PJ, et al. Influence of age on the pharmacokinetics of alfentanil. Clin Pharmacokinet 1990; 19: 416-422.
18. Sitar D, Duke PC, Benthuysen JL, et al. Aging and alfentanil disposition in healthy volunteers and surgical patients. Can J Anaesth 1989: 36: 149-154.
19. Mäenpää J, Hall SD, King HB, Strom SC, Wrighton SA. Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998; 8: 137-155.
20. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263: 424-436.
21. Jounaidi Y, Guzelian PS, Maurel P, Vilarem MJ. Sequence of the 5′-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem Res Commun 1994; 205: 1741-1747.
22. Merkatz RB, Temple R, Sobel S, Feiden K, Kessler DA. Women in clinical trials of new drugs: a change in food and drug administration policy. N Engl J Med 1993; 329: 292-296.
23. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997; 87: 26-35.
24. Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 1999; 39: 275-280.
25. Guengerich FP. Inhibition of oral contraceptive steriod - metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 1990; 163: 2159-2163.
26. Teichmann AT. Influence of oral contraceptives on drug therapy. Am J Obstet Gynecol 1990; 163: 2208-2213.
27. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472-484.